Quest Diagnostics Inc
NYSE:DGX

Watchlist Manager
Quest Diagnostics Inc Logo
Quest Diagnostics Inc
NYSE:DGX
Watchlist
Price: 163.59 USD -0.18% Market Closed
Market Cap: 18.3B USD
Have any thoughts about
Quest Diagnostics Inc?
Write Note

Quest Diagnostics Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Quest Diagnostics Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Quest Diagnostics Inc
NYSE:DGX
Current Portion of Long-Term Debt
$603m
CAGR 3-Years
745%
CAGR 5-Years
-6%
CAGR 10-Years
39%
DaVita Inc
NYSE:DVA
Current Portion of Long-Term Debt
$296.3m
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
9%
Chemed Corp
NYSE:CHE
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CVS Health Corp
NYSE:CVS
Current Portion of Long-Term Debt
$4.9B
CAGR 3-Years
47%
CAGR 5-Years
5%
CAGR 10-Years
24%
Cigna Corp
NYSE:CI
Current Portion of Long-Term Debt
$937m
CAGR 3-Years
244%
CAGR 5-Years
-23%
CAGR 10-Years
23%
Laboratory Corporation of America Holdings
NYSE:LH
Current Portion of Long-Term Debt
$1.4B
CAGR 3-Years
387%
CAGR 5-Years
23%
CAGR 10-Years
31%
No Stocks Found

Quest Diagnostics Inc
Glance View

Market Cap
18.3B USD
Industry
Health Care

Quest Diagnostics Inc. is a leading provider of diagnostic testing and information services, playing a crucial role in the healthcare ecosystem. With a legacy dating back to the 1960s, Quest has established itself as a trusted partner for healthcare providers by offering a wide range of testing services, including routine blood tests, genetic testing, and specialized diagnostics for chronic diseases. The company's innovative approach to testing, bolstered by its extensive network of laboratories and state-of-the-art technology, ensures accurate and timely results, empowering patients and physicians alike to make informed healthcare decisions. As an industry leader, Quest not only aids in clinical decision-making but also plays a pivotal role in the ongoing shift toward value-based care, which emphasizes quality over quantity in patient treatment. For investors, Quest Diagnostics represents an attractive opportunity due to its strong financial performance and growth potential. The company benefits from a robust demand for diagnostic testing services, especially in the wake of the COVID-19 pandemic, which has heightened awareness of the importance of timely medical diagnostics. Quest's investment in cutting-edge technology and telehealth solutions positions it well to adapt to the evolving healthcare landscape. With a track record of consistent revenue growth and a commitment to returning value to shareholders through dividends and share buybacks, Quest Diagnostics stands out as a solid investment in the healthcare sector, blending stability with innovation in a critical industry.

DGX Intrinsic Value
147.89 USD
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Quest Diagnostics Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
603m USD

Based on the financial report for Sep 30, 2024, Quest Diagnostics Inc's Current Portion of Long-Term Debt amounts to 603m USD.

What is Quest Diagnostics Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
39%

Over the last year, the Current Portion of Long-Term Debt growth was 98%. The average annual Current Portion of Long-Term Debt growth rates for Quest Diagnostics Inc have been 745% over the past three years , -6% over the past five years , and 39% over the past ten years .

Back to Top